Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2

ClinicalTrials.gov ID: NCT03093324

Public ClinicalTrials.gov record NCT03093324. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 6, 2026, 2:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3 Study in Subjects With Relapsing Remitting Multiple Sclerosis to Evaluate the Tolerability of ALKS 8700 and Dimethyl Fumarate

Study identification

NCT ID
NCT03093324
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Biogen
Industry
Enrollment
506 participants

Conditions and interventions

Interventions

  • ALKS 8700 Drug
  • Dimethyl Fumarate Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 14, 2017
Primary completion
Jun 26, 2019
Completion
Jun 26, 2019
Last update posted
Jul 13, 2020

2017 – 2019

United States locations

U.S. sites
57
U.S. states
25
U.S. cities
50
Facility City State ZIP Site status
Alkermes Investigational Site Cullman Alabama 35058
Alkermes Investigational Site Phoenix Arizona 85004
Alkermes Investigational Site Tucson Arizona 85704
Alkermes Investigational Site Long Beach California 90806
Alkermes Investigational Site San Diego California 92103
Alkermes Investigational Site Basalt Colorado 81621
Alkermes Investigational Site Centennial Colorado 80112
Alkermes Investigational Site Denver Colorado 80209
Alkermes Investigational Site Middlebury Connecticut 06762
Alkermes Investigational Site Stamford Connecticut 06905
Alkermes Investigational Site Washington D.C. District of Columbia 20007
Alkermes Investigational Site Atlantis Florida 33462
Alkermes Investigational Site Bradenton Florida 34209
Alkermes Investigational Site Maitland Florida 32751
Alkermes Investigational Site Naples Florida 34105
Alkermes Investigational Site Ormond Beach Florida 32174
Alkermes Investigational Site Sarasota Florida 34233
Alkermes Investigational Site Tampa Florida 33634
Alkermes Investigational Site Vero Beach Florida 32960
Alkermes Investigational Site Atlanta Georgia 30312
Alkermes Investigational Site Atlanta Georgia 30327
Alkermes Investigational Site Atlanta Georgia 30342
Alkermes Investigational Site Columbus Georgia 31904
Alkermes Investigational Site Evanston Illinois 60201
Alkermes Investigational Site Des Moines Iowa 50314
Alkermes Investigational Site Lenexa Kansas 66214
Alkermes Investigational Site Alexandria Louisiana 71301
Alkermes Investigational Site Detroit Michigan 48202
Alkermes Investigational Site Golden Valley Minnesota 55422
Alkermes Investigational Site St Louis Missouri 63104
Alkermes Investigational Site St Louis Missouri 63110
Alkermes Investigational Site St Louis Missouri 63131
Alkermes Investigational Site Albuquerque New Mexico 87106
Alkermes Investigational Site Patchogue New York 11772
Alkermes Investigational Site Stony Brook New York 11794
Alkermes Investigational Site Syracuse New York 13210
Alkermes Investigational Site Charlotte North Carolina 28203
Alkermes Investigational Site Greensboro North Carolina 27405
Alkermes Investigational Site Winston-Salem North Carolina 27103
Alkermes Investigational Site Canton Ohio 44718
Alkermes Investigational Site Columbus Ohio 43221
Alkermes Investigational Site Dayton Ohio 45417
Alkermes Investigational Site Oklahoma City Oklahoma 73104
Alkermes Investigational Site Charleston South Carolina 29406
Alkermes Investigational Site Greer South Carolina 29650
Alkermes Investigational Site Old Point Station South Carolina 29707
Alkermes Investigational Site Spartanburg South Carolina 29307
Alkermes Investigational Site Franklin Tennessee 37064
Alkermes Investigational Site Knoxville Tennessee 37922
Alkermes Investigational Site Dallas Texas 75231
Alkermes Investigational Site Houston Texas 77030
Alkermes Investigational Site Houston Texas 77074
Alkermes Investigational Site Newport News Virginia 23601
Alkermes Investigational Site Richmond Virginia 23226
Alkermes Investigational Site Seattle Washington 98101
Alkermes Investigational Site Seattle Washington 98122
Alkermes Investigational Site Seattle Washington 98133

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 10 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03093324, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 13, 2020 · Synced May 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03093324 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →